Dr S. Shahzad Mustafa discusses three FDA approved medications for chronic spontaneous urticaria and the need to tailor ...

In patients with chronic spontaneous urticaria, biomarkers such as a positive chronic urticaria index and low blood histamine ...

When Yard Act headlined the O2 Academy in Glasgow back in 2023, they might have thought returning there as a support act ...

The approval marks the first for a targeted treatment in chronic spontaneous urticaria in Europe in over a decad ...

European Commission approves Sanofi & Regeneron’s Dupixent to treat moderate-to-severe chronic spontaneous urticaria: Paris Wednesday, November 26, 2025, 14:00 Hrs [IST] The Eur ...

Dupilumab enhances quality of life in chronic urticaria patients unresponsive to antihistamines. Find out how treatment can ...

In September 2025, the US Food and Drug Administration (FDA) approved Rhapsido ® (remibrutinib), an oral small molecule kinase inhibitor, for the treatment of chronic spontaneous urticaria (CSU) in ...

BTS V once suffered from heat hives, also known as cholinergic urticaria. Learn its symptoms, causes, treatment, and how to prevent sweat-triggered hives.

Among adults with chronic spontaneous urticaria inadequately controlled by H1 antihistamine treatment, remibrutinib improved ...

As treatment options have expanded for the treatment of chronic spontaneous urticaria (CSU), the question of which one works best has gained importance. The anti-immunoglobulin E (IgE) antibody ...

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria ...

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the ...